J&J's Cordis escapes $593M stent patent infringement loss

April 4, 2013 by Brad Perriello

A federal appeals court reverses a $593 million patent infringement loss for Johnson & Johnson's Cordis stent-making arm.

Cordis Corp.

Johnson & Johnson (NYSE:JNJ) logged a major win for its Cordis stent-making arm today when a federal appeals court overturned a lower court decision to award more than $593 million to stent pioneer Dr. Bruce Saffran for patent infringement.

Saffran alleged that Cordis violated his patent with the Cypher drug-eluting stent, leading to a jury trial that went Saffran's way.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.